Type of information: Grant
Company: Evotec (Germany)
Investors: Hamburgische Investitions- und Förderbank (IFB Hamburg) (Germany)
Funding type: grant
Planned used: The grant will be used to identify and develop therapeutic antibodies directed against novel immune-checkpoints on T-cells to improve future cancer treatments. It will fund a programme focused on demonstrating pre-clinical activity for at least one first-in-class antibody against novel immune-checkpoints active against patient-derived tumour cells. This EVT Innovate-anchored programme is designed to utilise synergies between Evotec’s infrastructure for the identification of novel therapeutic antibodies and Evotec’s collaboration partner, the University Medical Center Hamburg-Eppendorf , for the long-term understanding of immunological mechanisms, antibody-based cancer therapies and oncological screening.
Therapeutic area: Cancer - Oncology